Testing a new oral medication for active juvenile arthritis in children

Plain-English translation of NCT07554495 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated September 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a medication called to see if it is safe and works well for children and teenagers (ages 8–17) with polyarticular-course juvenile idiopathic arthritis—a type of persistent joint inflammation that affects multiple joints. Researchers want to understand how the medication works in the body and whether it can reduce pain and swelling when other treatments haven't been enough.

Many children with this type of arthritis don't respond well enough to current treatments, leaving them with ongoing pain and joint damage. This trial exists to see whether this medication could provide better control of the disease for young patients who need more effective options.

Do you qualify?

You likely qualify if…

you are between 8 and 17 years old
you have been diagnosed with polyarticular-course juvenile idiopathic arthritis (including extended oligoarthritis, RF-positive or RF-negative polyarthritis, psoriatic arthritis, or enthesitis-related arthritis)
your arthritis is moderately to severely active and not well controlled by your current treatment
you have tried and either not tolerated or not responded well to at least one standard arthritis medication (such as methotrexate or a biologic drug) for at least 3 months
you and your parent or guardian are willing to follow the study protocol and attend all visits

You likely don't qualify if…

you weigh less than 33 pounds (15 kg)
you have an active or uncontrolled eye inflammation (anterior uveitis) within the past 12 weeks
you have systemic juvenile idiopathic arthritis (the type that affects the whole body)
you have an active infection or a serious history of herpes zoster (shingles)
you have other autoimmune or inflammatory diseases such as inflammatory bowel disease, lupus, or immunodeficiency disorders

What participation looks like

You would take orally (by mouth) as a daily medication for up to 18 weeks. During this time, you would attend clinic visits where researchers will check how the medication is working, monitor for any side effects, take blood samples, and assess your joint pain and swelling. The study is "open-label," meaning everyone knows they are receiving the medication—there is no placebo group.

AI-generated summary from trial data · Sep 11, 2026 · Not medical advice

Trial locations(14 sites)

Belgium

UZ Leuven, Leuven

Czechia

Vseobecna fakultni nemocnice v Praze, Prague

France

Hôpital Bicêtre, Le Kremlin-Bicêtre

Germany

Charité - Campus Virchow-Klinikum, Berlin

Hamburger Zentrum fuer Kinder und Jugendrheumatologie, Hamburg